Product Name
LEMD3, siRNA
Full Product Name
LEMD3 siRNA (Mouse)
Product Synonym Names
MAN1; Inner nuclear membrane protein Man1; LEM domain-containing protein 3
Product Gene Name
LEMD3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9WU40
Specificity
LEMD3 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse LEMD3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of LEMD3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
LEMD3 sirna
siRNA to inhibit LEMD3 expression using RNA interference
Applications Tested/Suitable for LEMD3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for LEMD3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001074662.2
[Other Products]
NCBI GenBank Nucleotide #
NM_001081193.2
[Other Products]
UniProt Primary Accession #
Q9WU40
[Other Products]
UniProt Secondary Accession #
Q0VGU6; Q3USB5[Other Products]
UniProt Related Accession #
Q9WU40[Other Products]
Molecular Weight
102,739 Da
NCBI Official Full Name
inner nuclear membrane protein Man1
NCBI Official Synonym Full Names
LEM domain containing 3
NCBI Official Symbol
Lemd3??[Similar Products]
NCBI Official Synonym Symbols
Man1; AI316861
??[Similar Products]
NCBI Protein Information
inner nuclear membrane protein Man1
UniProt Protein Name
Inner nuclear membrane protein Man1
UniProt Synonym Protein Names
LEM domain-containing protein 3
Protein Family
Inner nuclear membrane protein
UniProt Gene Name
Lemd3??[Similar Products]
UniProt Synonym Gene Names
Man1??[Similar Products]
UniProt Entry Name
MAN1_MOUSE
UniProt Comments for LEMD3
MAN1: Can function as a specific repressor of TGF-beta, activin, and BMP signaling through its interaction with the R-SMAD proteins. Antagonizes TGF-beta-induced cell proliferation arrest. Defects in LEMD3 are the cause of Buschke-Ollendorff syndrome (BOS); also known as dermatoosteopoikilosis or disseminated dermatofibrosis with osteopoikilosis or dermatofibrosis lenticularis disseminata with osteopoikilosis or osteopathia condensans disseminata. BOS refers to the association of osteopoikilosis with disseminated connective-tissue nevi. Osteopoikilosis is a skeletal dysplasia characterized by a symmetric but unequal distribution of multiple hyperostotic areas in different parts of the skeleton. Both elastic-type nevi (juvenile elastoma) and collagen-type nevi (dermatofibrosis lenticularis disseminata) have been described in BOS. Skin or bony lesions can be absent in some family members, whereas other relatives may have both. Defects in LEMD3 are a cause of melorheostosis (MEL). Melorheostosis is a rare mesenchymal dysplasia and one of the sclerosing bone disorders. It is caused by a developmental error, with a sclerotomal distribution, frequently involving one limb. It may be asymptomatic, but pain, stiffness with limitation of motion, leg-length discrepancy and limb deformity may occur.
Protein type: Membrane protein, integral; Nuclear envelope; Membrane protein, multi-pass
Cellular Component: membrane; integral to membrane; nuclear inner membrane; nuclear envelope; integral to nuclear inner membrane; nucleus
Molecular Function: DNA binding; nucleotide binding
Biological Process: blood vessel endothelial cell migration during intussusceptive angiogenesis; negative regulation of activin receptor signaling pathway; regulation of cell cycle; angiogenesis; negative regulation of transforming growth factor beta receptor signaling pathway; nuclear organization and biogenesis; negative regulation of BMP signaling pathway
Research Articles on LEMD3
1. a nuclear envelope-localized mechanism of inactivating TGF-beta signaling in which MAN1 competes with transcription factors for binding to Smad2 and Smad3 and facilitates their dephosphorylation by PPM1A.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
